Introduction
Hepatocellular carcinoma (HCC), is the predominant form of primary liver cancer, the fifth most common malignancy, and the fourth leading cause of cancer-related death globally.1–3 Major risk factors for HCC have been well established and include hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, abnormalities of lipid metabolism, excessive alcohol consumption, intake of dietary toxins like aristolochic acid or aflatoxin B1, diabetes.3 HCC is a biologically complex and highly heterogeneous disease, and the detailed mechanisms underlying hepatocarcinogenesis are still poorly understood. In recent decades, various preventive and therapeutic approaches have been approved and widely applied in HCC management, including antihepatitis vaccine, surgical resection, liver transplantation, and systemic treatment, etc.4,5 Notably, cancer immunotherapies have achieved pronounced clinical benefits, however, a large proportion of the immunotherapies still remain ineffective.6 Considering that worldwide mortality from HCC is continuously increasing, it is important to improve our understanding of the molecular pathogenesis of HCC, while novel diagnostic/prognostic biomarkers and therapeutic strategies are urgently needed to deal with this major public health concern.
It is now clear that tumor formation and progression involve the co-evolution of neoplastic cells and surrounding stromal components. In recent years, the TIME has received significant attention as it is recognized to closely interact and co-evolve with tumor cells, affecting tumor growth, metastasis, immune escape, and the efficacy of immunotherapy. The TIME of HCC is a highly intricate and integrated system that consists of diverse cellular and noncellular components. The cellular components comprise immune cells including macrophages, neutrophils, myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, dendritic cells (DCs), T cells, B cells, cancer stem cells (CSCs), hepatic stellate cells (HSCs), vascular cells, cancer-associated fibroblasts (CAFs), and other stromal cells. The noncellular parts include the extracellular matrix and abundant soluble factors (e.g., cytokines, chemokines, growth factors) (Fig. 1). All these components dynamically interact to foster an immunosuppressive TIME. Many studies have revealed that TIME has a critical role in regulating immune evasion and the development of HCC.6–9 However, the detailed molecular mechanisms underlying TIME reprogramming in HCC are not understood.
Noncoding RNAs (ncRNAs) refer to transcripts with no or minimal protein-coding ability. In the human genome, less than 2% of the transcripts encode proteins, while the remaining 98% are transcribed into different species of ncRNAs. ncRNAs can be classified into two major categories based on their molecular structure, including linear RNAs and circular RNAs (circRNAs). The linear RNAs can be broadly divided into two groups by their length, small noncoding RNAs (sncRNAs, <200 nt) and long noncoding RNAs (lncRNAs, >200 nt). sncRNAs consist of microRNAs (miRNAs), small nucleolar RNAs (snoRNAs), transfer RNA-derived small RNAs (tsRNAs), and PIWI-interacting RNAs (piRNAs).10,11 Emerging evidence has shown that ncRNAs can reprogram TIME, which has profound influences on HCC tumorigenesis and progression. In this review, we systematically discuss the functional roles and molecular mechanisms of ncRNAs within the TIME of HCC, and discuss the diagnostic/therapeutic potential of ncRNAs in HCC treatment.
NcRNAs and innate immune cells in TIME
The TIME of HCC is a complex ecosystem that has various types of innate immune cells and adaptive immune cells, both have established roles in host defense against tumors through diverse mechanisms. Innate immune cells establish the body’s first line of defense against tumors, set up by macrophages, neutrophils, MDSCs, NK cells, and DCs, which recognize and act on tumor cells nonspecifically to maintain homeostasis of the host. However, under pathological conditions like cancer, the immune responses of these cells are often disturbed by TIME, which may fuel tumor growth and progression. Recently, extensive studies have indicated that ncRNAs exert a vital role in regulating the differentiation, activation, recruitment, and function of various innate immune cells during the pathogenesis of HCC, which will be discussed in the section below (Table 1, Fig. 2).12–26
Table 1ncRNAs involved in the regulation of innate immune cells
| NcRNA | Expression in HCC | Related immune cell | Target molecules/pathways | Function in TIME | Impact on HCC | Reference |
|---|
| miR-28-5p | Downregulated | TAMs | IL-34/FAK/ERK1/2 | Promote TAM recruitment and infiltration into HCC tissue | Promote angiogenesis, tumor growth, and metastasis | 12 |
| circASAP1 | Upregulated | TAMs | miR-326/miR-532-5p/CSF-1 | Promote TAM infiltration | Promote HCC growth and metastasis | 13 |
| hsa_circ_0110102 | Downregulated | TAMs | miR-580-5p/PPARα/CCL2 | Inhibit macrophage activation and infiltration | Inhibit HCC growth and metastasis | 14 |
| lncRNA LINC00662 | Upregulated | TAMs | miR-15a/16/107/WNT3A/Wnt/β-catenin | Promote M2 macrophage polarization | Promote tumor growth and metastasis | 15 |
| lncRNA PART1 | Upregulated | TAMs | miR-372-3p/TLR4 axis | Promote M2 macrophage polarization | Promote HCC cell proliferation, EMT, and metastasis | 16 |
| lncRNA TUC339 | Upregulated | TAMs | NA | Promote macrophage activation, M2 polarization, and pro-tumorigenic activity | Promote HCC progression | 17 |
| hsa_circ_0003410 | Upregulated | TAMs | miR-139-3p/CCL5 | Recruit and polarize M2 macrophages | Promotes HCC tumor growth and metastasis | 18 |
| miR-223 | Downregulated | Neutrophils | NA | Attenuate neutrophil maturation and activation | Inhibit HCC progression | 19 |
| miR-122 | Downregulated | Neutrophils | CCL2 | Inhibit recruitment of neutrophils | Inhibit tumor progression | 20 |
| miR-561-5p | Upregulated | NKs | CX3CL1/ CX3CR1+/STAT3 | Inhibit CX3CR1+ NK-cell infiltration and activation | Promote pulmonary metastasis | 22 |
| circRNA UHRF1 | Upregulated | NKs | miR-449c-5p/TIM-3 | Induce NK-cell exhaustion and promote NK-cell dysfunction | Promote immune evasion and resistance to anti-PD1 therapy | 23 |
| lncRNA GAS5 | Downregulated | NKs | miR-544/RUNX3 | Enhance the killing effect of NK cells | Inhibit immune evasion and tumor progression | 24 |
| circRNA hsa_circ_0007456 | Downregulated | NKs | miR-6852-3p/ICAM-1 | Strengthen the cytotoxicity of NK cells | Inhibit immune evasion and inhibit tumor growth | 25 |
| circRNA ARSP91 | Downregulated | NKs | ULBP1 | Strengthen the cytotoxicity of NK cells | Enhance innate immune surveillance, suppress HCC proliferation | 26 |
| lncRNA HOTAIR | Upregulated | MDSCs | CCL2 | Promote recruitment of MDSCs | Promote tumor growth and metastasis | 21 |
NcRNAs and macrophages
Macrophages are the major component of the innate immune cells within TIME. It is acknowledged that macrophages largely originate from circulating bone marrow-derived monocytes.27 Macrophages are a highly plastic and heterogeneous cell population whose phenotypes and functions are regulated by the surrounding microenvironment. In response to specific microenvironmental stimuli, macrophages generally polarize into two phenotypes, classically activated macrophages (M1) and alternatively activated macrophages (M2). M1 macrophages elicit pro-inflammatory effects and have an antitumorigenic role. Conversely, M2 macrophages enhance anti-inflammatory response and have pro-tumorigenic functions. Most tumor-associated macrophages (TAMs) in the tumor have an M2 phenotype. Under the inductions of various signaling molecules in TIME, TAMs are recruited to the primary and metastatic tumor tissues where they suppress the immune response by secreting a plethora of pro-tumorigenic proteases, cytokines, chemokines, and growth factors, and promote tumor growth, migration, invasion, angiogenesis, and immunosuppression.28,29
An increasing number of studies show the extensive involvement of ncRNAs in macrophage recruitment and polarization in multiple cancer types, including HCC. For example, in HCC, miR-28-5p deficiency promotes the expression of interleukin (IL)-34, and activates FAK and ERK1/2 signaling in macrophages, leading to enhanced recruitment and infiltration of macrophages into HCC tumor sites.12 Similarly in another study, highly expressed circASAP1 in HCC cells functions as a competitive endogenous RNA (ceRNA) that sponges miR-326 and miR-532-5p, alleviating the repression of CSF-1 expression. CSF-1, as a potent chemoattractant, survival, and differentiation factor for macrophages,30 positively modulates TAM infiltration to HCC tumor bed, which is considered to contribute to HCC growth and metastasis.13 Another circRNA hsa_circ_0110102, which is markedly downregulated in HCC cell lines, triggers macrophage activation and hepatic infiltration via miR-580-5p/PPARα/CCL2 pathway, while increasing the production and release of pro-inflammatory cytokines COX-2/PGE2 from macrophages, and ultimately enhancing HCC cell proliferation, migration, and invasion.14
Uncontrolled macrophage polarization is commonly implicated in HCC progression, and deregulation of ncRNAs plays an essential role in mediating M1/M2 macrophage polarization. As an example, LINC00662 induces macrophage M2 polarization in a paracrine manner to potentiate HCC tumor growth and metastasis. Mechanistic studies reveal that LINC00662 acts as a ceRNA for miR-15a/16/107 to stimulate WNT3A expression and secretion from HCC cells. WNT3A then activates Wnt/β-catenin pathway in macrophages, triggering their polarization toward the M2 subtype.15 It is also reported that lncRNA PART1 is transferred from HCC cells to surrounding macrophages via HCC cell-derived extracellular vesicles (EVs) that triggers macrophage polarization toward the M2 subtype by targeting miR-372-3p/TLR4 axis.16 Similarly, TUC339, a lncRNA enriched in HCC-secreted exosomes, is transmitted from HCC cells to peri-tumor macrophages and greatly affects macrophage polarization and activity. Overexpression of TUC339 in human macrophage cell lines THP-1 contributes to M2 phenotype, polarization, and decreased phagocytic activity, decreased pro-inflammatory cytokine (IL1β and TNF-α) production, reduced costimulatory molecule expression, and augmented viability of macrophages, therefore diminishing the antitumor immune response against tumor cells.17 Cao et al.18 found that upregulated_circ_0003410 in HCC cells promoted HCC tumor growth and metastasis by elevating the ratio of M2/M1 macrophage. Mechanistically, hsa_circ_0003410 stimulates the expression of CCL5 by competitively binding miR-139-3p to recruit and polarize M2 macrophages. Many other ncRNAs have been shown to change M1/M2 macrophage polarization, such as lncRNA MALAT1,31 lncRNA TP73-AS1,32 hsa_circ_0074854,33 which promote M2 polarization, and lncRNA cox-2,34 lncRNA GAS5,35 which inhibit M2 polarization.
Both ncRNAs expressed in HCC cells or exosomal ncRNAs secreted by HCC cells are known to orchestrate macrophage recruitment, polarization, and activity, and macrophages reciprocally impact HCC cell behavior by regulating ncRNAs. Intercellular communication between tumor cells and microenvironmental stromal cells mediated by ncRNAs have a strong impact on HCC initiation and malignant progression. A notable example is the miR-28-5p. Specifically, TAMs induced and recruited to HCC tissues by the miR-28-5p/IL-34/FAK/ERK1/2 signaling axis suppressed the expression of miR-28-5p in HCC cells by secretion of TGF-β1, hence forming an miR-28-5p/IL-34/TAM/TGF-β1 positive feedback loop to modulate HCC growth and metastasis.12 A study by Liu et al.36 reported that miR-92a-2-5p in exosomes transported from tumor-infiltrating macrophages to HCC tumor cells increased the invasive capacity of HCC tumor cells by altering the intrinsic AR/PHLPP/p-AKT/β-catenin signaling. Likewise, RBPJ-overexpressed macrophages transmit hsa_circ_0004658 to neighboring HCC cells via shuttling exosomes, which restrains proliferation and induces apoptosis in HCC cells through the miR-499b-5p/JAM3 pathway.37
ncRNAs and neutrophils
Neutrophils, generated in the bone marrow from myeloid precursors, participate in innate immunity against cancer. Like macrophages, neutrophils have various polarization phenotypes with either tumor-suppressive or tumor-promoting immune function. Tumor-associated neutrophils (TANs) can mediate cytotoxicity toward tumor cells. Besides, TANs also promote tumor growth and metastasis by stimulating angiogenesis, orchestrating the behavior of other immune cells, and enhancing tumor cell motility, migration, and invasion.38,39 Increased neutrophil infiltration has been linked to HCC progression and poor prognosis in patients with HCC.40 Mounting evidence has indicated that ncRNAs participate in controlling the activation, polarization, recruitment, and function of neutrophils in multiple cancer types, but it remains largely unexplored in HCC.8,9 MiR-223 is abundantly expressed in neutrophil cells and serves as a modulator of neutrophils in many advanced liver diseases, including HCC and hepatitis virus infection, cirrhosis, nonalcoholic fatty liver disease, and alcohol-induced liver injury, which are important risk factors of HCC. Functionally, miR-223 has a critical role in attenuating neutrophil maturation and activation, although the exact molecular mechanism has not been clarified.19,41 In another study by Hsu et al.,20 by examining the immune cells that infiltrate hepatic parenchyma in miR-122-KO mice and control group, found that miR-122 depletion stimulated recruitment of neutrophils to the liver, driving hepatic inflammation and producing a higher level of tumor-promoting cytokines. Mechanism dissection reveals that miR-122 deficiency triggers neutrophil recruitment through upregulating CCL2. As the cellular behavior and function of neutrophils are regulated by HCC-derived exosomes, further investigation of the contents of the exosomes is warranted.42
NcRNAs and MDSCs
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells predominately originating from bone marrow precursor cells. Under pathological conditions like HCC, MDSCs and expand accumulate in TIME, and have strong immunosuppressive activity that impairs various immune responses, such as T-cell function, therefore contributing to tumorigenesis and tumor progression.43 Several studies have implicated ncRNAs in the differentiation, expansion, and immunosuppressive function of MDSCs,44–46 their contribution to developing HCC is not clear. A recent study showed that strong expression of lncRNA HOTAIR in HCC cell lines was positively associated with enhanced recruitment of MDSCs. The proportion of MDSCs in peripheral blood mononuclear cells (PBMCs) increased when they were co-cultured with HCC cells overexpressing HOTAIR. It was further confirmed that HOTAIR increased the secretion of CCL2 from HCC cells into the tumor milieu. CCL2 was a well-documented chemoattractant and was speculated to be responsible for the HOTAIR-mediated accumulation of MDSCs into the TIME.21
NcRNAs and NK cells
Natural killer (NK) cells are an indispensable part of the innate immune system and a subgroup of innate lymphoid cells. They are primarily developed in the bone marrow and migrate into the blood circulation as they mature. The status of NK-cell activation is dictated by the interactions between specific ligands and diverse activating or inhibitory receptors expressed on the NK-cell surface. NK cells have cytotoxic activity and can directly kill target cells. Beyond its cytotoxic capacity, NK cells are also producers of large amounts of cytokines, chemokines, and growth factors that contribute to innate and adaptive immune responses, such as interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), CCL3. Therefore, NK cells can also influence the immune state and function of other immune cells in TIME.47–49 Thus, NK cells mainly serve as important players in boosting antitumor immune response against tumors. NK-cell dysfunction can lead to severe immune deficiency that allows tumor cells to escape immune surveillance and thrive in the TIME. It is noteworthy that NK-cell dysfunction has been reported in the TIME of HCC,50 but the mechanism underlying the abnormal behavior of NK cells in HCC is unknown.
To the best of our knowledge, studies describing the role of ncRNAs in mediating NK-cell activity, including infiltration, activation, exhaustion, and function during HCC progression are increasing. Chen et al.22 found that upregulation of miR-561-5p expression suppressed CX3CR1+ NK-cell infiltration and activation by targeting CX3CL1, thereby promoting HCC tumorigenesis and pulmonary metastasis. miR-561-5p in HCC tumor cells reduced secretion of CX3CL1, a chemokine known to be associated with lymphocyte migration. Loss of CX3CL1 in TIME interfered with chemotaxis and activation of CX3CR1+ NK cells by inactivating STAT3 signaling in NK cells. As CX3CR1+ NK cells have strong tumor-killing activity, inhibiting the infiltration and cytotoxic activity of CX3CR1+ NK cells enabled HCC cells to escape immune surveillance, and promoted HCC proliferation and metastasis. A recent study reported that HCC cell-derived exosomal circUHRF1 contributed to immune evasion and resistance to anti-PD1 immunotherapy in HCC by inducing NK-cell exhaustion and suppressed IFN-γ and TNF-α production in NK cells. circUHRF1-mediated exhaustion and dysfunction of NK cells was attributed to increased expression of inhibitory receptor TIM-3 in NK cells.23
In HCC, the cytotoxicity of NK cells is governed by multiple ncRNAs. Low expression of the lncRNA GAS5 in the NK cells of HCC patients inhibits cytotoxic activity and accelerates tumor metastasis. Mechanistic studies show that lncRNA GAS5 deficiency inhibited RUNX3 expression in NK cells by upregulating miR-544, which suppressed the NCR1/NKp46 axis. NKp46 is a stimulatory receptor on the NK cell surface, and its inactivation impairs the killing activity of NK cells. The evidence indicates that the miR-544/RUNX3/NCR1/NKp46 pathway accounted for the GAS5-mediated regulation of NK-cell cytotoxicity.24,51 Another study reported that downregulated hsa_circ_0007456 in HCC cells reduced the cytotoxicity of NK cells toward tumor cells, which promoted immune evasion and aggressiveness of HCC. To be specific, hsa_circ_0007456 deficiency restored miR-6852-3p level and interfered with the expression of ICAM-1. ICAM-1 was reported to regulate the adhesion of cancer cells and NK cells. Hsa_circ_0007456-mediated interference of ICAM-1 decreased the susceptibility of HCC cells to NK cytolysis.25–53 Similarly, circRNA ARSP91 was found to enhance the cytotoxicity of NK cells toward HCC cells by upregulating UL16 binding protein 1, an NKG2D ligand that activates stimulatory receptors associated with the tumor-killing function of NK cells.26,54,55 Many other ncRNAs are also known to modulate the cytotoxicity of NK cells against HCC cells, such as miR-615-5p,56 miR-146a,57 miR-30c-1,58 and miR-506.59 The available evidence supports a role of ncRNAs in the regulation of NK cells during the development of HCC. Some of the ncRNAs may be potential therapeutic targets to enhance the efficacy of NK cell-based anticancer immunotherapy in the treatment of HCC.
ncRNAs and DCs
DCs are considered the most efficient antigen-presenting cells with a key role in linking innate and adaptive immune system. They take up and process antigens, converting them into peptides that are presented to T cells by major histocompatibility complex molecules that trigger activation and protective immune responses. In the tumor milieu, normal DC activity is disturbed and often has immunosuppressive and tolerogenic effects that boosts the malignant progression of tumors.60,61 Studies of dendritic cells in HCC are relatively scarce despite considerable evidence showing they have a critical role in many malignancies. ncRNAs have been shown to regulate the development, differentiation, recruitment, and function of DCs in many cancers, but their regulatory roles in the pathogenesis of HCC have not been extensively studies.8,9,62 In recent years, several ncRNAs were reported to mediate the infiltration of dendritic cells in HCC. For example, Wu et al.63 found that the expression level of lncRNA ASB16-AS1 was negatively correlated with tumor-infiltrating neutrophils in HCC, as shown by CIBERSORT, TIMER, xCell, quanTIseq, EPIC and MCP-counter.63 The CIBERSORT algorithm confirmed that that MIR210HG was negatively correlated with, and LINC01224 was positively correlated, with DC infiltration.64 The detailed molecular mechanisms were not described in the studies.
ncRNAs and adaptive immune cells in TIME
Despite being prominent regulators for many types of innate immune cells within TIME of HCC, emerging evidence has revealed that ncRNAs also participate in the regulation of adaptive immune cells, including various T and B cell subgroups (Table 2, Fig. 2).65–73
Table 2ncRNAs involved in the regulation of adaptive immune cells
| NcRNA | Expression in HCC | Related immune cell | Target molecules/pathway | Function in TIME | Impact on HCC | Reference |
|---|
| lncRNA NEAT1 | Upregulated | CD8+ T cells | miR-155/Tim-3 | Induce CD8+ T cells apoptosis and dampen its cytolysis activity against HCC cells | Promote immune evasion and tumor progression | 65 |
| lncRNA lnc-Tim3 | Upregulated | CD8+ T cells | Tim-3/Bat3/Lck/ZAP70/AP-1/NF-AT1 and Bat3/p300/p53/RelA | Stimulate CD8+ T-cell exhaustion | Promote immunosuppression and tumor growth | 66 |
| circRNA circMET | Upregulated | CD8+ T lymphocytes | miR-30-5p/Snail/DPP4/CXCL10 | Stimulate CD8+ lymphocyte infiltration | Enhance immunosuppression | 67 |
| microRNA-132 | Upregulated | Th17 | SNIP1 | Promote Th17 differentiation and function | Promote HCC cell migration and EMT | 68 |
| microRNA-34a | Downregulated | Tregs | CCL22 | Suppress Treg recruitment | Enhance immune surveillance, suppress tumor growth, and metastasis | 69 |
| lncRNA EGFR | Upregulated | Tregs | EGFR/AP-1/NF-AT1 | Stimulate Treg differentiation, inhibit CTL activity | Promote immunosuppression and HCC growth | 70 |
| circRNA circGSE1 | Upregulated | Tregs | miR-324-5p/TGFBR1/Smad3/FOXP3 axis | Induce the expansion of Tregs | Promote immune escape, enhance tumor growth and metastasis | 71 |
| lncRNA FENDRR | Downregulated | Tregs | miR-423-5p/GADD45B | Inhibit Treg infiltration | Suppress immune escape and tumor growth | 72 |
| lncRNA LINC00261 | Downregulated | B cells | miR105-5p/SELL | Promote B-cell dysfunction | Promote HCC progression | 73 |
ncRNAs and T cells
T lymphocytes are the primary effector cells in cellular immunity and include subsets with distinct roles in immunity and immune-mediated pathologies.74 Cytotoxic T cells (CTLs) kill and eradicate malignant cells.75 T-helper (Th) cells are differentiated from CD4+ T cells and have subpopulations with either pro- or antitumorigenic activity in the tumor milieu.76 Regulatory T cells (Tregs) are differentiated from CD4+ T cells and suppress antitumor responses of other immune cells, with immunosuppressive activity in the TIME. Infiltration of a large number of Tregs into tumor tissue is often associated with poor prognosis.77 Additionally, In the setting of HCC, recent studies have shown that substantial changes in the expression profiles of ncRNAs occur during T-cell development, activation, and differentiation, indicating a crucial role of ncRNAs in regulating T-cell activity.
Increasing evidence shows the pivotal role of ncRNAs in mediating the antitumor response of CTLs against malignant HCC cells. For example, lncRNA NEAT1 was shown to contribute to the immune escape of HCC by affecting the antitumor activity of CD8+ T cells. The lncRNA NEAT1 was significantly upregulated in the PBMCs of HCC patients, and overexpression of lncRNA NEAT1 induced CD8+ T-cell apoptosis and impaired the cytolysis of HCC cells via regulating miR-155/Tim-3 signaling. Tim-3 is an inhibitory immune checkpoint receptor expressed on T cells; its activation enforces T-cell exhaustion and induces T-cell apoptosis and dysfunction.65,78 The lncRNA lnc-Tim3 was shown to stimulate CD8+ T-cell exhaustion by targeting Tim-3, and was linked to immunosuppression and malignant behavior in HCC. Mechanistically, lnc-Tim3 competitively bound to Tim-3 in CD8+ T cells, resulting in release of Bat3 from the C-terminal end of Tim-3 and accumulation of the catalytically inactive form of Lck, which suppressed downstream T-cell signaling (ZAP70/AP-1/NF-AT1 signaling) and endogenous cytokine production (IL2/IFN-γ). The released Bat3 formed a complex with p300, which increased its nuclear translocation and enhanced p300-dependent p53 and RelA transcriptional activation of anti-apoptosis genes and promoted survival of Tim-3+ exhausted CD8+ T cells. The dual mechanism contributed to CD8+ T-cell exhaustion.66 In addition, the circRNA circMET is preferentially expressed in HCC tumors and associated with poor clinical outcomes. CircMET overexpression hinders CD8+ T-cell infiltration in HCC tissues through the miR-30-5p/Snail/DPP4/CXCL10 axis, which enhances the immunosuppressive properties of TIME that favor HCC cell survival and metastasis.67
Th cell differentiation results from regulation of genes and involves transcription factors, including STAT3, RUNX-1, and others.79 However, ncRNAs are also emerging as important regulators of Th cell differentiation. Feng et al.68 observed that overexpression of miR-132 promoted Th17 differentiation and production of IL22 and IL17 possibly by targeting of the downstream protein SNIP1. IL22 activated hepatic stellate cells (HSCs), which then promoted HCC cell migration and epithelial-mesenchymal transition (EMT).68
ncRNAs are also implicated in the modulation of Tregs in HCC. For example, HBV infection-activated TGF-β signaling suppresses the expression of microRNA-34a, resulting in increased production of CCL22, which facilitates recruitment of CD4+CD25+ Tregs into the TIME. Sustained activation of TGF-β-miR-34a-CCL22 axis promotes the development of intrahepatic venous metastasis in HCC patients via generating an immunosuppressive TIME that favors tumor cell survival and dissemination.69 ncRNAs have also been found to participate in the differentiation of Tregs during HCC development, as shown by lncRNA lnc-EGFR. Lnc-EGFR is highly expressed in Tregs of HCC patients and is positively correlated with HCC immune evasion and tumor growth. Lnc-EGFR specifically binds to epithelial growth factor receptor (EGFR) and stabilizes it by blocking its ubiquitination by c-CBL. Persistent activation of EGFR triggers a. downstream signaling cascade (RAS/ERK/AP-1/NF-AT1). It is important to note that the NF-AT transcription factors are widely expressed in a variety of leukocytes, including T cells, and regulate genes involved in lymphocyte development. lnc-EGFR-activated AP-1/NF-AT1 signaling has been shown to stimulate Treg differentiation, as shown by an increased ratio of Tregs in CD4+ T cells and in TIME. Intriguingly, the AP-1/NF-AT1 complex enhanced transcription of lnc-EGFR, EGFR, and Foxp3 by binding to their promoters, thus forming a forward-feedback loop in Tregs that impaired antitumor immunity and promoted HCC progression.70 Similarly, exosomal circGSE1 from HCC cells promoted immune escape, tumor growth, and metastasis by promoting Treg differentiation and proliferation by regulating an miR-324-5p/TGFBR1/Smad3/FOXP3 axis.71 In addition, Yu et al.72 reported that poorly expressed lncRNA FENDRR in HCC cells acted an miR-423-5p sponge to downregulate GADD45B, enhance the immune-suppressive activity of Tregs, and allow HCC cells to escape from immune surveillance.72 Taken together, the studies underscore the crucial role of ncRNAs in T cell-mediated immunosuppression and might inspire immunotherapy.
NcRNAs and B cells
The importance of T cells in tumor immune surveillance is well established, but the contribution of B cells has been studied to a much lesser extent. B cells contribute to humoral immunity by producing antibodies. Recent advances in B-cell biology have revealed that B cells participate in antigen presentation, promote T-cell responses, and release a variety of cytokines. B cell subsets have protumor or antitumor activities, including regulatory B cells with immunosuppressive activity.80,81 Recent studies have shown tumor-infiltrating B cells were associated with tumor progression and immunotherapy response in human cancers, including HCC.82–84 The regulatory role of ncRNAs during B-cell development, differentiation, apoptosis, and function have been described,8,85,86 but little is known of ncRNA-mediated B-cell regulation of the pathogenesis of HCC. A recent bioinformatics analysis revealed that the LINC00261/MiR105-5p/SELL signaling axis was involved in B-cell dysfunction and was associated with overall survival in HCC patients. Details of the molecular mechanism were not clarified.73
ncRNAs and other stromal components in the TIME
In addition to immune cells, CSCs, HSCs, CAFs, and many other stromal cells are components of the TIME in HCC.6 Evidence of the regulatory effects of ncRNAs on a variety of nonimmune cells is increasing (Table 3, Fig. 2).87–92–99
Table 3ncRNAs involved in the regulation of other stromal cells in TIME
| NcRNA | Expression in HCC | Related stromal cell | Target molecules/pathways | Function in TIME | Impact on HCC | References |
|---|
| lncRNA lncTCF7 | Upregulated | CSCs | TCF7/Wnt signaling | Promote self-renewal of human liver CSCs | Promote tumor propagation | 87 |
| lncRNA lnc-β-Catm | Upregulated | CSCs | EZH2/Wnt-β-catenin | Sustain liver CSC self-renewal | Promote tumor propagation | 88 |
| lncRNA LncBRM | Upregulated | CSCs | YAP signaling | Promote CSC self-renewal | Promote tumor propagation | 89 |
| lncRNA lncHDAC2 | Upregulated | CSCs | Hedgehog signaling | Promote self-renewal of liver CSCs | Promote tumor growth | 90 |
lncRNA
lncSOX4 | Upregulated | CSCs | STAT3/SOX4 signaling | Sustain liver CSC self-renewal | Promote tumor initiation | 91 |
| lncRNA lnc-DILC | Downregulated | CSCs | IL-6/JAK2/STAT3 a signaling | Suppress self-renewal of liver CSCs | Inhibit tumor initiation and progression | 92 |
| microRNA-145 | Downregulated | HSCs | ZEB2/Wnt-β-catenin | Repress HSC activation and proliferation | Repress liver fibrosis and tumorigenesis | 93 |
| microRNA-708 | Downregulated | HSCs | ZEB1/Wnt-β-catenin | Repress HSC activation and proliferation | Repress liver fibrosis and tumorigenesis | 94 |
| lncRNA-MEG3 | Downregulated | HSCs | miR-212/SMO/Hh signaling | Inhibit HSC activation | Inhibit liver fibrosis | 95 |
| microRNA-378 | Downregulated | HSCs | Hh signaling | Limit HSC activation | Inhibit liver fibrosis | 96 |
| microRNA-21 | Upregulated | HSCs, CAFs | PTEN/PDK1/AKT signaling | Convert HSCs to CAFs | Promote HCC angiogenesis | 97 |
| microRNA-124 | Downregulated | HSCs | IQGAP1/NF-κB axis | Inhibit cytokine secretion of HSCs | Reduce inflammatory response | 98 |
| miR-1247-3p | Upregulated | CAFs | B4GALT3, β1-integrin/NF-κB axis | Induce CAF activation | Foster lung metastasis of HCC | 99 |
ncRNAs and CSCs
Cancer stem cells (CSCs) are a rare population of cells within the tumor bulk that share many intrinsic features with normal stem cells, such as self-renewal and differentiation. CSCs have been found to exist in many solid tumors, including HCC. The stem-cell like properties of liver CSCs may contribute to the heterogeneity, resistance to treatment, metastasis, and high rate of recurrence of HCC, which makes CSCs an attractive target for cancer therapy.100,101 Recently, increasing studies have described the ability of ncRNAs to modulate self-renewal, differentiation, and stemness of liver CSCs through activating diverse CSC-related signaling pathways, such as Wnt-β-catenin signaling, YAP signaling, Hedgehog signaling, STAT3 signaling, TGF-β signaling, or cell cycle-related signaling.101 LncRNA lncTCF7 and lnc-β-Catm, both are seen highly expressed in HCC tumor tissues and liver CSCs and correlate with poor prognosis in HCC, promote self-renewal maintenance of liver CSCs through activation of Wnt-β-catenin signaling pathway. Mechanistically, lncTCF7 recruits the SWI/SNF chromatin remodeling complex to the promoter region of target gene TCF7 to promote its transcription. TCF7 then triggers downstream Wnt signaling cascade, which primes the self-renewal of liver CSCs and tumor propagation. Lnc-β-Catm associates with EZH2 to catalyze methylation of β-catenin, thus hindering β-catenin ubiquitination and stabilizing it, allowing β-catenin to start Wnt signaling and sustain the self-renewal of liver CSCs.87,88 Similarly, lncBRM sequesters BRM to form BRG1-BAF complex, starting YAP1 signaling in liver CSCs, which drives CSC self-renewal process.89 lncHDAC2 is highly expressed in the CD13+CD133+ subset of liver CSCs, where it contributes to self-renewal maintenance by recruiting the nucleosome remodeling and deacetylase (NuRD) complex to promote PTCH1 and activate Hedgehog signaling.90 Another lncRNA lncSOX4 mediates liver CSCs self-renewal via STAT3-SOX4 signaling axis. LncSOX4 interacts with and recruits STAT3 to bind to SOX4 promoter, triggering SOX4 expression, which is required for liver CSCs self-renewal and tumor initiation.91 In addition, lncRNA-DILC is examined significantly downregulated in EPCAM+ CSCs; it abrogates IL6 transcription and abolishes STAT3 activation, thus repressing self-renewal and expansion of liver CSCs. Lnc-DILC depletion helps with HCC start and progression.92
NcRNAs and HSCs
HSCs play vital roles in the tumorigenesis and progression of HCC, largely because activation of HSCs contributes to hepatic fibrosis. HSCs can secrete a variety of bioactive contents to maintain liver inflammation and regulate tumor-associated pathways, which then trigger immunosuppression, angiogenesis, and therapy resistance of HCC. Under pathological conditions, HSCs are changed from the quiescent stage to the active stage, and the activated HSCs eventually differentiate into myofibroblast-like cells.102,103 Increasing studies have described the molecular mechanisms underlying HSC activation, and ncRNAs emerge as prominent participants in the regulation of HSC activation. For example, as the Wnt-β-catenin signaling pathway is documented to be generally hyperactivated in HSCs during liver fibrosis to orchestrate cell activation, proliferation, and maintain homeostasis,104 many ncRNAs have been revealed to regulate HSC activation via Wnt-β-catenin pathway, as exampled by microRNA-145 and microRNA-708. MicroRNA-145 and microRNA-708 are both poorly expressed in fibrotic liver tissues and activated HSCs, and their deregulations are both able to activate the Wnt-β-catenin pathway via increasing expression of ZEB2 and ZEB1, respectively. The hyperactivated Wnt-β-catenin pathway thus accelerates the activation and proliferation of HSCs.93,94 Hedgehog (Hh) signaling is another cascade activated in HSCs and regulates hepatic fibrogenesis. Hh signaling is also regulated by various ncRNAs, such as lncRNA-MEG3, microRNA-378, etc. LncRNA-MEG3 inhibits Hh signaling-mediated EMT process in HSC activation via associating with SMO protein and sponging miR-212. While microRNA-378 limits HSC activation by suppressing Gli3 expression, which is a downstream transcription factor of Hh signaling.95,96 Zhou et al.97 identified that tumor-derived exosomal miRNA-21 was internalized by HSCs and it directly targeted phosphatase and tensin homolog (PTEN), resulting in activation of PDK1/AKT signaling in HSCs, which primed the conversion from normal HSCs to CAFs and promoted angiogenesis of HCC. ncRNAs can also impair the HSC function to produce inflammatory cytokines. One such example is microRNA-124, which inhibits HSC secretion of TNF-α, IL-1β, and IL-6 by targeting the IQGAP1/NF-κB axis.98
ncRNAs and CAFs
As the most important and abundant component of the stromal cell population in TIME, CAFs are crucial players during the occurrence and malignant progression of HCC. Upon stimulation by the TIME, fibroblasts are activated and converted into CAFs. CAFs have been reported to modulate HCC progression through diverse mechanisms, including remodeling the extracellular matrix, secreting soluble factors or exosomes, and regulating the behavior of various immune cells, which can either potentiate or oppose HCC progression.105–107 Many ncRNAs are known to regulate CAF formation and activation during HCC development. For example, the abovementioned HCC cell-derived miR-21 could convert HSCs into CAFs via targeting PTEN and activating PDK1/AKT signaling cascade in HSCs. Activated CAFs release various angiogenic factors to stimulate angiogenesis in HCC tumors.97 Fang and colleagues unveil that HCC cell-derived exosomal miR-1247-3p potentiates CAFs activation to foster lung metastasis of HCC. Mechanistically, miR-1247-3p is transferred from HCC cells to fibroblasts in lung pre-metastasis niche via exosomes. MiR-1247-3p subsequently drives normal fibroblast transformation to CAFs by decreasing its target gene B4GALT3 expression to activate β1-integrin-NF-κB signaling. Activated CAFs promote stemness, EMT, chemoresistance, and tumorigenicity of HCC cells by releasing IL-6 and IL-8.99 Finally, dynamic intercellular communications mediated by exosomes are widely seen between CAFs and HCC cells and strongly affect HCC progression and therapy response.108 Therefore, as a major cargo in exosomes, ncRNAs are speculated to play important roles during the interaction, which deserves further elucidation.
Diagnostic/therapeutic potential of ncRNAs in HCC
One reason leading to the high mortality of HCC is that a significant percentage of patients is diagnosed at advanced stages. The diagnosis of HCC relies on serum α-fetoprotein measurement and ultrasonography imaging, etc. However, these diagnostic modalities still remain insufficient, especially for diagnosis of early-stage HCC.5 Therefore, novel biomarkers with higher sensitivity and specificity are urgently needed. Emerging evidence indicates that a myriad of ncRNAs show aberrant and tissue-specific/cell-specific expression patterns in HCC, and many are detectable and relatively stable in body fluids. These unique properties of ncRNAs make them promising noninvasive biomarkers for HCC detection. Besides, ncRNAs also display prognostic value since the expression levels of multiple ncRNAs are closely correlated with tumor stage and clinical outcomes of HCC, such as metastasis and recurrence.11 In addition, certain ncRNAs that modulate resistance are proven to be associated with treatment response, indicating their potential to predict treatment response.23,109 Of note, many ncRNAs are encapsulated in circulating exosomes, which protect them from being degraded by RNase. And exosomal ncRNA detection has the advantage of noninvasive, repeatable, and real-time tracking.110,111 Taken together, ncRNAs could serve as potential diagnostic/prognostic biomarkers, however, further efforts must validate the sensitivity and specificity of them as biomarkers.
Despite a lack of reliable biomarkers, effective therapeutic options/targets are also limited for HCC treatment.5 Recently, ncRNAs have been documented to play widespread roles in gene regulation and participate in diverse signaling cascades.112 Most important, ncRNAs function as a pivotal regulator in TIME during HCC progression by influencing the differentiation, activation, recruitment, and function of various types of cells within TIME, including diverse immune cells and many other nonimmune stromal cells. The ncRNA-mediated regulation of the TIME and cancer type-specific deregulation of ncRNAs indicate that ncRNAs are highly promising therapeutic targets for HCC treatment. To date, many approaches have been developed to target ncRNAs and govern their expression or function, including small molecule inhibitors, aptamers, antisense oligonucleotides, RNA interference, and CRISPR/Cas9 gene editing technology.113–115 RNA-based therapeutic method is still in its infancy and many difficulties and limitations have emerged during its application. For example, difficulty of using antisense oligonucleotides is to optimize their specific delivery to target cells and to augment their stability in vivo.113 One challenge of CRISPR/Cas9 is to avoid adverse off-target effects. Besides, there are concerns like whether these treatments might cause unwanted side effects, such as affecting other parts within TIME.112,114 In addition, many ncRNAs exist in regulatory feedback loops, thus, it might be difficult to modulate their expression. Overcoming these challenges will improve the efficacy of these RNA-based cancer therapies.
It is important to highlight that ncRNA-based therapy is a promising approach in HCC immunotherapy. Given their vital roles in TIME, it might be possible to modulate the immune response of multiple immune cells within TIME by manipulating the expression pattern of specific ncRNA, such as facilitating recruitment of various antitumor immune cells to the tumor site, enhancing cytotoxicity of NK cells, inhibiting the function of immunosuppressive cells, which could be effective to boost antitumor immune response and restrain immune escape, ultimately hindering tumor growth and malignant progression. In addition, targeting different ncRNAs combined with other therapeutic strategies might show significant benefit in the treatment of HCC. For example, given that circUHRF1 has been proven to drive resistance to anti-PD1 immunotherapy in HCC patients,23 the combined therapy of ncRNA-targeted drugs and anti-PD1 immunotherapy may therefore display synergistic effects in inhibiting tumor progression.
Conclusions and perspectives
TIME is an integrated system consisting of diverse cellular and noncellular parts. It closely interacts with tumors and greatly contributes to the occurrence and progression of HCC. And as summarized in this review, ncRNA is emerging as a prominent regulator in reprogramming the TIME of HCC. An impressive number of ncRNAs exhibit aberrant expression patterns in HCC, and they can modulate the development, biological behavior, and function of various cell types within the TIME, which ultimately elicit profound influences on tumorigenesis, tumor growth, metastasis, angiogenesis, and immune evasion in HCC. Of note, the current knowledge regarding the regulatory role of ncRNAs in TIME principally focuses on miRNAs and lncRNAs, but novel classes of ncRNA like circRNAs and piRNAs await further investigation. Accumulating evidence has indicated ncRNAs as important mediator in the crosstalk between TIME and neoplastic cells in various cancer types, but their mediatory role has not been elucidated in HCC. Apart from focusing on regulating ncRNAs on TIME, it is also important to dissect the exact mechanisms of how ncRNAs are dysregulated in TIME of HCC, which lets us gain a more comprehensive understanding of the complex regulatory network between TIME and ncRNAs in HCC pathogenesis. Because of the roles of ncRNAs within TIME of HCC, novel diagnostic/prognostic biomarkers and therapeutic interventions based on ncRNAs are under development for treating HCC, however, the majority are still in the experimental stages due to various limitations. Further investigations must translate those research findings into clinical applications.
Abbreviations
- CAF:
cancer-associated fibroblast
- ceRNA:
competitive endogenous RNA
- circRNA:
circular RNA
- CSC:
cancer stem cell
- CTL:
cytotoxic T cell
- DC:
dendritic cell
- EMT:
epithelial-mesenchymal transition
- EV:
extracellular vesicle
- HBV:
hepatitis B virus
- HCC:
hepatocellular carcinoma
- HCV:
hepatitis C virus
- Hh signaling:
Hedgehog signaling
- HSC:
hepatic stellate cell
- lncRNA:
long noncoding RNA
- MDSC:
myeloid-derived suppressor cell
- miRNA:
microRNA
- NA:
not available
- ncRNA:
noncoding RNA
- NK cell:
natural killer cell
- PBMC:
peripheral blood mononuclear cell
- piRNA:
PIWI-interacting RNA
- sncRNA:
small noncoding RNA
- snoRNA:
small nucleolar RNA
- TAM:
tumor-associated macrophage
- TAN:
tumor-associated neutrophil
- Th cell:
T-helper cell
- TIME:
tumor immune microenvironment
- Treg:
regulatory T cell
- tsRNA:
transfer RNA-derived small RNA
Declarations
Funding
This work was supported by grants from the Science and Technology Major Program of Sichuan Province (2022ZDZX0019).
Conflict of interest
KY has been an editorial board member of Journal of Clinical and Translational Hepatology since 2023. The other authors have no conflicts of interest related to this publication.
Authors’ contributions
Drafting of the manuscript (YL), critical revision of the manuscript for important intellectual content (ZW, KY). All authors made significant contributions to the study and approved the final manuscript.